Odyssey Therapeutics' OD-001 Meets Primary Endpoint in Phase 2a Ulcerative Colitis Study

Odyssey Therapeutics announced that its investigational drug OD-001, an oral, selective RIPK2 scaffolding inhibitor, met its primary endpoint in a Phase 2a study for moderate-to-severe ulcerative colitis. The study showed a mean modified Mayo score reduction of 2.4 points at Week 12, with a p-value below 0.001. This positive result supports advancing a 20 mg twice-daily dose into Phase 2b trials.